SUPPORTING INFORMATION

Copper-catalyzed formal [1+2+2]-annulation of alkyne-tethered diazoacetates and pyridines: access to polycyclic indolizines

Shanliang Dong, a Jingjing Huang, b Hongkai Sha, b Lihua Qiu, a Wenhao Hub and Xinfang Xu*a, c

- ^a Key Laboratory of Organic Synthesis of Jiangsu Province, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China
- ^b Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
- ^c Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Rd., Shanghai 200062, China

E-mail: xinfangxu@suda.edu.cn.

Table of Contents

1. General Information	S2
2. General Procedure for the Preparation of Diazo Compounds 1	S2-S9
3. General Procedure for the Pyridine Derivatives 2	S9-S14
4. General Procedure for the Formal [1+2+2] Cycloaddition	S14-S32
4. 1D-NOE NMR Analysis and Control Experiments	S33-S36
5. General Procedure for Scale Up	S37
6. Derivatizations	S37-38
7. References	S38
8. NMR Spectra for Compounds 3, 4, 5, 7, 9 and 10	S39-S77
9. Single-crystal X-ray Diffraction of 3a and 10	S78-S79

General Information

All reactions were carried out in oven-dried glassware. Flash column chromatography was performed using silica gel (300-400 mesh). Analytical thin-layer chromatography was performed using glass plates pre-coated with 200-300 mesh silica gel impregnated with a fluorescent indicator (254 nm). ¹H NMR and ¹³C NMR spectra were recorded in CDCl₃ on a 400 MHz spectrometer; chemical shifts are reported in ppm with the solvent signal as reference, and coupling constants (*J*) are given in Hertz. The peak information is described as: br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, comp = composite. High-resolution mass spectra (HRMS) were recorded on a commercial apparatus (ESI or CI Source).

General Procedure for the Preparation of Diazo Compounds 1.



Synthesis of S-2: To a 250-mL oven-dried flask containing a magnetic stirring bar, S-1 (15.2 g, 100.0 mmol) was dissolved in MeOH (75.0 mL), then added H₂SO₄ (2.6 g, 10.0 mmol) slowly, and the reaction mixture was stirred at 65 °C for 36 hours. Then the reaction mixture was diluted with dichloromethane (20.0 mL) and washed with saturated NaHCO₃ (200.0 mL). The organic phase was dried over Na₂SO₄ and the solvent was evaporated in *vacuo* after filtration to give product S-2 in > 90% yields, which were directly used in the next step without further purification.



Synthesis of **S-4:** To a 50-mL oven-dried flask containing a magnetic stirring bar, **S-2** (1.7 g, 10.0 mmol), propargyl alcohol **S-3** (11.0 mmol, 1.1 equiv.), PPh₃ (3.9 g, 1.5 equiv.) in dry THF (30.0 mL), was added DIAD (3.0 g, 1.5 equiv.) slowly at 0 $^{\circ}$ C,

and the reaction mixture was stirred at room temperature for 4-5 hours. Upon completed (monitored by TLC), the reaction mixture was filtrated through a short pad of Celite, and the filtrate was evaporated in *vacuo*. The residue was purified by column chromatography on silica gel (Hexanes : EtOAc = 20:1) to give the pure products **S-4** in > 80% yields.



Synthesis of **1**: To a 50-mL oven-dried flask containing a magnetic stirring bar, compound **S-4** (5.0 mmol), *p*-ABSA (7.5 mmol) in dry CH₃CN (15 mL), was added DBU (10.0 mmol) in CH₃CN (5 mL) dropwise at 0°C. The resulting mixture was allowed to warm to room temperature over 30 min and stirred for additional 10 h. The reaction was quenched with aqueous NH₄Cl solution (60 mL) and then extracted with diethyl ether (20 mL), and the organic phase was dried over anhydrous Na₂SO₄. After evaporating the solvent after filtering through a short pad of Celite, the resulting residue was purified by column chromatography on silica gel (Hexanes : EtOAc = 20:1) to give pure **1** in >60% yields.



Methyl 2-diazo-2-(2-((3-phenylprop-2-yn-1-yl)oxy)phenyl)acetate (1a). Yellow solid; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.68 – 7.60 (m, 1H), 7.51 – 7.42 (m, 2H), 7.37 – 7.27 (comp, 4H), 7.16 – 7.05 (m, 2H), 4.96 (s, 2H), 3.84 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 166.6, 153.7, 131.8, 130.3, 128.8, 128.5, 128.4, 122.2, 122.0, 114.6, 112.8, 87.6, 83.4, 57.3, 52.0; HRMS (TOF MS ESI⁺) calculated for C₁₈H₁₄N₂O₃Na [M+Na]⁺: 329.0897, found 329.0899.



Methyl 2-(2-((3-(4-bromophenyl)prop-2-yn-1-yl)oxy)phenyl)-2-diazoacetate (1b). Yellow oil; ¹H NMR (400 MHz, CDCl₃) (δ, ppm) 7.61 – 7.59 (m, 1H), 7.45 – 7.35 (m, 2H), 7.35 – 7.20 (comp, 3H), 7.08 – 7.03 (m, 2H), 4.90 (s, 2H), 3.81 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ, ppm) 166.5, 153.6, 133.2, 131.6, 130.3, 128.5, 123.1, 122.1, 121.1, 114.6, 112.8, 86.5, 84.6, 57.2, 52.0; HRMS (TOF MS ESI⁺) calculated for C₁₈H₁₃BrN₂O₃Na [M+Na]⁺: 407.0002, found 406.9996.



Methyl 2-(2-((3-(4-chlorophenyl)prop-2-yn-1-yl)oxy)phenyl)-2-diazoacetate (1c). Yellow oil; ¹H NMR (400 MHz, CDCl₃) (δ, ppm) 7.67 – 7.56 (m, 1H), 7.40 – 7.32 (m, 2H), 7.30 – 7.25 (comp, 3H), 7.12 – 7.05 (m, 2H), 4.95 (s, 2H), 3.84 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ, ppm) 166.7, 153.8, 135.0, 133.1, 130.4, 128.8, 128.6, 122.2, 120.7, 114.7, 112.8, 86.5, 84.4, 57.3, 52.1; HRMS (TOF MS ESI⁺) calculated for C₁₈H₁₃ClN₂O₃Na [M+Na]⁺: 363.0507, found 363.0515.



Methyl 2-diazo-2-(2-((3-(4-methoxyphenyl)prop-2-yn-1-yl)oxy)phenyl)acetate (1d). Yellow oil; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.63 – 7.60 (m, 1H), 7.42 – 7.35 (m, 2H), 7.29 (m, 1H), 7.15 – 7.05 (m, 2H), 6.88 – 6.82 (m, 2H), 4.95 (s, 2H), 3.84 (s, 3H), 3.81 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 166.7, 160.1, 153.9, 133.4, 130.3, 128.5, 122.0, 114.6, 114.3, 114.0, 112.9, 87.6, 82.1, 57.5, 55.4, 52.1; HRMS (TOF MS ESI⁺) calculated for C₁₉H₁₆N₂O₄Na [M+Na]⁺: 359.1002, found



Methyl 2-diazo-2-(2-((3-(2-methoxyphenyl)prop-2-yn-1-yl)oxy)phenyl)acetate (1e). Yellow solid; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.60 – 7.57 (m, 1H), 7.38 –7.36 (m, 1H), 7.30 – 7.24 (m, 2H), 7.15 –7.13(m, 1H), 7.09 – 7.03 (m, 1H), 6.95 – 6.79 (m, 2H), 4.98 (s, 2H), 3.84 (s, 3H), 3.81 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 166.7, 160.3, 153.9, 133.9, 130.3, 130.2, 128.5, 121.9, 120.5, 114.5, 113.0, 111.4, 110.7, 87.4, 84.1, 57.6, 55.8, 52.0; HRMS (TOF MS ESI⁺) calculated for C₁₉H₁₆N₂O₄Na [M+Na]⁺: 359.1008, found 359.1017.



Methyl 2-diazo-2-(2-((3-(4-(trifluoromethyl)phenyl)prop-2-yn-1-yl)oxy)phenyl) acetate (1f). Yellow oil; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.64 – 7.49 (comp, 5H), 7.32 – 7.27 (m, 1H), 7.13 – 7.04 (m, 2H), 4.98 (s, 2H), 3.84 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 166.6, 153.6, 132.0, 130.7, 130.4 (d, *J* = 3.1 Hz), 128.5, 125.9 (q, *J* = 1.5 Hz), 125.3 (q, *J* = 3.8 Hz), 122.5, 122.2, 114.6, 112.7, 57.1, 52.0; ¹⁹F NMR (376 MHz, CDCl₃) (δ , ppm) -62.91. HRMS (TOF MS ESI⁺) calculated for C₁₉H₁₃F₃N₂O₃Na [M+Na]⁺: 397.0770, found 397.0767.



Methyl 2-diazo-2-(2-((3-(4-fluorophenyl)prop-2-yn-1-yl)oxy)phenyl)acetate (1g).

Yellow oil; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.63 – 7.60 (m, 1H), 7.45 – 7.38 (m, 2H), 7.32 – 7.26 (m, 1H), 7.12 – 7.06 (m, 2H), 7.04 – 6.98 (m, 2H), 4.95 (s, 2H), 3.84 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 166.7, 162.9 (d, *J* = 250.1 Hz), 153.8, 133.9 (d, *J* = 8.5 Hz), 130.4, 128.6, 122.4, 118.3 (d, *J* = 3.6 Hz), 115.7 (d, *J* = 22.1 Hz), 114.7, 112.9, 86.6, 83.2, 57.3, 52.1; ¹⁹F NMR (376 MHz, CDCl₃) (δ , ppm) -110.06. HRMS (TOF MS ESI⁺) calculated for C₁₈H₁₃FN₂O₃Na [M+Na]⁺: 347.0802, found 347.0797.



Methyl 2-diazo-2-(2-((3-(3-fluorophenyl)prop-2-yn-1-yl)oxy)phenyl)acetate (1h). Yellow solid, ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.63 – 7.60 (m, 1H), 7.32 – 7.25 (m, 2H), 7.23 – 7.20 (m, 1H), 7.15 – 7.03 (comp, 4H), 4.96 (s, 2H), 3.84 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 166.7, 162.4 (d, *J* = 246.7 Hz), 153.8, 130.5, 130.1 (d, *J* = 8.6 Hz), 128.6, 127.8 (d, *J* = 3.1 Hz), 124.0 (d, *J* = 9.5 Hz), 122.2, 118.7 (d, *J* = 22.9 Hz), 116.29 (d, *J* = 21.1 Hz), 116.2, 114.7, 112.9, 86.4, 84.4, 57.2, 52.1.; ¹⁹F NMR (376 MHz, CDCl₃) (δ , ppm) -112.72. HRMS (TOF MS ESI⁺) calculated for C₁₈H₁₃FN₂O₃Na [M+Na]⁺: 347.0802, found 347.0790.



Methyl 2-diazo-2-(2-((3-(2-fluorophenyl)prop-2-yn-1-yl)oxy)phenyl)acetate (1i). Yellow oil; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.64 – 7.61 (m, 1H), 7.46 – 7.42 (m, 1H), 7.37 – 7.28 (m, 2H), 7.18 – 7.02 (comp, 4H), 5.00 (s, 2H), 3.85 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 166.6, 162.9 (d, J = 252.2 Hz), 153.7, 133.7, 130.6 (d, J = 8.0 Hz), 130.3, 128.5, 124.0 (d, J = 3.9 Hz), 122.1, 115.6 (d, J = 20.7 Hz), 114.6, 112.8, 110.7 (d, J = 15.6 Hz), 88.6, 81.0, 57.2, 52.0; ¹⁹F NMR (376 MHz, CDCl₃) (δ , ppm) -109.78. HRMS (TOF MS ESI⁺) calculated for C₁₈H₁₃FN₂O₃Na [M+Na]⁺: 347.0802, found 347.0791.



Methyl 2-diazo-2-(2-((3-(naphthalen-1-yl)prop-2-yn-1-yl)oxy)phenyl)acetate (1j). Yellow solid; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.25 – 8.21 (m, 1H), 7.88 – 7.83 (m, 2H), 7.70 – 7.66 (m, 2H), 7.59 – 7.50 (m, 2H), 7.44 – 7.41 (m, 1H), 7.39 – 7.30 (m, 1H), 7.21 – 7.19 (m, 1H), 7.15 – 7.11 (m, 1H), 5.12 (s, 2H), 3.84 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 166.6, 153.7, 133.3, 133.1, 130.8, 130.4, 129.3, 128.5, 128.3, 127.0, 126.5, 126.1, 125.2, 122.1, 119.8, 114.8, 113.0, 88.2, 85.8, 57.4, 52.0; HRMS (TOF MS ESI⁺) calculated for C₂₂H₁₆N₂O₃Na [M+Na]⁺: 379.1053, found 379.1062.



Methyl 2-diazo-2-(2-((3-(thiophen-2-yl)prop-2-yn-1-yl)oxy)phenyl)acetate (1k). Yellow solid; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.65 – 7.63 (m, 1H), 7.36 – 7.23 (comp, 3H), 7.17 – 7.09 (m, 2H), 7.00 – 6.98 (m, 1H), 4.99 (s, 2H), 3.86 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 166.6, 153.7, 133.0, 130.3, 128.5, 127.9, 127.1, 122.1, 122.0, 114.6, 112.8, 87.4, 80.9, 57.3, 52.0; HRMS (TOF MS ESI⁺) calculated for C₁₆H₁₂N₂O₃SNa [M+Na]⁺: 335.0461, found 335.0460.



Methyl 2-(2-(but-2-yn-1-yloxy)phenyl)-2-diazoacetate (11). Yellow oil; ¹H NMR

(400 MHz, CDCl₃) (δ , ppm) 7.62 – 7.59 (m, 1H), 7.30 – 7.25 (m, 1H), 7.16 – 6.97 (m, 2H), 4.71 (t, J = 2.4 Hz, 2H), 3.85 (s, 3H), 1.87 (t, J = 2.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 166.6, 153.8, 130.2, 128.4, 121.7, 114.3, 112.6, 84.1, 83.2, 73.6, 56.9, 51.9; HRMS (TOF MS ESI⁺) calculated for C₁₃H₁₂N₂O₃Na [M+Na]⁺: 267.0740, found 267.0739.



Methyl 2-diazo-2-(2-((1,4-diphenylbut-3-yn-2-yl)oxy)phenyl)acetate (1m). Yellow solid; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.72 – 7.70 (m, 1H), 7.54 – 7.42 (comp, 6H), 7.42 – 7.32 (comp, 5H), 7.27 – 7.26 (m, 1H), 7.18 – 7.14 (m, 1H), 5.29 – 5.26 (m, 1H), 3.90 (s, 3H), 3.55 – 3.43(m, 2H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 166.5, 153.6, 136.3, 131.7, 130.4, 129.7, 128.7, 128.43, 128.39, 128.3, 127.0, 122.1, 122.0, 114.7, 114.2, 87.7, 86.5, 70.6, 51.9, 42.2; HRMS (TOF MS ESI⁺) calculated for C₂₅H₂₀N₂O₃Na [M+Na]⁺: 419.1372, found 419.1378.



Methyl 2-diazo-2-(2-((4-phenylbut-3-yn-2-yl)oxy)phenyl)acetate (1n). Yellow oil; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.70 – 7.61 (m, 1H), 7.47 – 7.39 (m, 2H), 7.37 – 7.27 (comp, 4H), 7.24 (d, J = 8.2 Hz, 1H), 7.16 – 7.04 (m, 1H), 5.15 (d, J = 6.5 Hz, 1H), 3.86 (s, 3H), 1.91 – 1.78 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 166.7, 153.4, 131.8, 130.1, 128.7, 128.3, 122.2, 121.9, 114.5, 113.9, 87.7, 86.1, 65.2, 52.0, 22.2; HRMS (TOF MS ESI⁺) calculated for C₁₉H₁₆N₂O₃Na [M+Na]⁺: 343.1053, found 343.1048.



Methyl 2-diazo-2-(2-(prop-2-yn-1-yloxy)phenyl)acetate (1q). Yellow oil; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.62 – 7.60 (m, 1H), 7.29 – 7.25 (m, 1H), 7.10 – 7.00 (m, 2H), 4.73 (d, J = 2.5 Hz, 2H), 3.84 (s, 3H), 2.57 (t, J = 2.4 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 166.4, 153.3, 130.2, 128.4, 122.0, 114.4, 112.5, 77.9, 76.0, 56.2, 51.9; HRMS (TOF MS ESI⁺) calculated for C₁₂H₁₀N₂O₃Na [M+Na]⁺: 253.0584, found 253.0579.





To a 50-mL oven-dried flask containing a magnetic stirring bar, **S-5** (0.676 g, 5.5 mmol, 1.1 equiv.), and alcohol **S-6** (5.0 mmol, 1.0 equiv.) in DCM (20 mL), was added DMAP (61.0 mg, 0.5 mmol, 10.0 mol%) and DCC (1.25 g, 6.0 mmol, 1.2 equiv.) in sequence at 0 °C. Then the reaction mixture was stirred for 4-5 hours at room temperature. Upon completed (monitored by TLC), the solvent was evaporated under vacuum after filtering through a short pad of Celite. The residue was purified by column chromatography on silica gel (Hexanes : EtOAc = 10:1) to give the pure products **2** as white solid with > 90% yields.



(3*S*,8*R*,9*S*,10*R*,13*S*,14*S*)-10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17 -tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl isonicotinate (2A). White solid; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.84 – 8.59 (m, 2H), 7.87 – 7.73 (m, 2H), 5.43 (d, *J* = 5.1 Hz, 1H), 4.90 – 4.82 (m, 1H), 2.47 – 2.40 (comp, 3H), 2.18 – 2.03 (m, 2H), 2.01 – 1.88 (comp, 3H), 1.86 – 1.78 (m, 1H), 1.76 – 1.59 (comp, 4H), 1.59 – 1.46 (m, 2H), 1.36 – 1.12 (comp, 4H), 1.07 (s, 3H), 0.87 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 164.5, 150.5, 139.6, 138.0, 123.0, 122.5, 75.5, 51.8, 50.2, 47.6, 38.1, 37.0, 36.8, 35.9, 31.53, 31.47, 30.9, 27.8, 22.0, 20.4, 19.5, 13.6; HRMS (TOF MS ESI⁺) calculated for C₂₅H₃₁NO₃Na [M+Na]⁺: 416.2202, found 416.2200.



(3*S*,8*R*,9*S*,10*S*,13*S*,14*S*)-10,13-dimethyl-17-oxohexadecahydro-1*H*-cyclopenta[*a*]p henanthren-3-yl isonicotinate (2B). White solid; ¹H NMR (400 MHz, CDCl₃) (δ, ppm) 8.73 – 8.46 (m, 2H), 7.84 – 7.52 (m, 2H), 4.86 – 4.78(m, 1H), 2.32 – 2,25 (m, 1H), 1.97 – 1.87 (m, 1H), 1.86 – 1.75 (m, 2H), 1.72 – 1.57 (comp, 4H), 1.57 – 1.47 (m, 2H), 1.46 – 1.31 (m, 3H), 1.27 – 1.07 (comp, 6H), 1.01 – 0.93 (m, 1H), 0.91 – 0.81 (m, 1H), 0.76 (s, 3H), 0.72 (s, 3H), 0.65 – 0.56 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) (δ,

ppm) 164.3, 150.3, 137.8, 122.6, 74.9, 54.1, 51.1, 47.5, 44.4, 36.5, 35.6, 35.5, 34.8, 33.7, 31.3, 30.6, 28.1, 27.2, 21.6, 20.3, 13.6, 12.1; HRMS (TOF MS ESI⁺) calculated for C₂₅H₃₃NO₃Na [M+Na]⁺: 418.2358, found 413.2344.



(8*R*,9*S*,10*R*,13*S*,14*S*,17*S*)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17 -tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-17-yl isonicotinate (2C). White solid; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.78 (d, *J* = 4.6 Hz, 2H), 7.90 – 7.77 (m, 2H), 5.81 – 5.66 (m, 1H), 4.89 – 4.84(m, 1H), 2.46 – 2.27 (comp, 5H), 2.05 – 2.00(m, 1H), 1.91 – 1.83 (m, 2H), 1.78 – 1.58 (comp, 5H), 1.49 – 1.38 (m, 2H), 1.32 – 1.25 (m, 1H), 1.20 (s, 3H), 1.18 – 0.99 (comp, 3H), 0.97 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 199.5, 170.8, 165.0, 150.5, 138.1, 124.2, 123.0, 84.1, 53.8, 50.4, 43.1, 38.7, 36.8, 35.8, 35.5, 34.0, 32.8, 31.6, 27.7, 23.7, 20.7, 17.5, 12.4; HRMS (TOF MS ESI⁺) calculated for C₂₅H₃₃NO₃Na [M+Na]⁺: 416.2202, found 416.2212.



(3*S*,8*S*,9*S*,10*R*,13*R*,14*S*,17*R*)-10,13-dimethyl-17-((*R*)-6-methylheptan-2-yl)-2,3,4,7, 8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl **isonicotinate (2D).** White solid; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.77 – 8.54 (m, 2H), 7.91 – 7.62 (m, 2H), 5.35 (d, *J* = 4.3 Hz, 1H), 4.84 – 4.76 (m, 1H), 2.40 (d, *J* = 8.0 Hz, 2H), 1.98 – 1.64 (comp, 8H), 1.55 – 1.39 (comp, 6H), 1.30 – 1.10 (comp, 8H), 1.06 – 0.92 (comp, 8H), 0.85 (d, *J* = 6.4 Hz, 3H), 0.82 – 0.79 (comp, 5H), 0.62 (d, *J* = 4.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 164.3, 150.5, 139.2, 137.9, 123.1, 122.8, 75.5, 56.6, 56.2, 50.0, 42.3, 39.5, 38.0, 36.6, 36.2, 35.8, 34.9, 31.8, 28.2, 28.0, 27.7, 25.5, 24.7, 24.3, 23.9, 22.8, 22.6, 21.0, 19.3, 18.7, 11.8; HRMS (TOF MS ESI⁺) calculated for C₃₃H₄₉NO₂Na [M+Na]⁺: 514.3661, found 514.3673.



(3*S*,8*S*,9*S*,10*R*,13*R*,14*S*,17*R*)-17-((2*R*,5*R*)-5-ethyl-6-methylheptan-2-yl)-10,13-dim ethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenan thren-3-yl isonicotinate (2E). White solid; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.76 (d, *J* = 5.3 Hz, 2H), 7.88 – 7.82 (m, 2H), 5.45 – 5.40 (m, 1H), 4.92 – 4.88(m, 1H), 2.52 – 2.43 (m, 2H), 2.03 – 1.91 (comp, 4H), 1.86 – 1.77(m, 2H), 1.69 – 1.60 (m, 2H), 1.55 – 1.43 (comp, 5H), 1.31 – 1.14 (comp, 10H), 1.08 – 1.04 (m, 5H), 0.94 – 0.91 (comp, 4H), 0.87 – 0.81 (comp, 10H), 0.69 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 164.5, 150.4, 139.4, 138.3, 123.3, 123.1, 75.8, 56.8, 56.2, 50.2, 46.0, 42.5, 39.8, 38.2, 37.1, 36.8, 36.3, 34.1, 32.1, 31.99, 29.3, 28.4, 27.9, 26.2, 24.4, 23.2, 21.1, 20.0, 19.5, 19.2, 18.9, 12.1, 12.0; HRMS (TOF MS ESI⁺) calculated for C₃₅H₅₃NO₂Na [M+Na]⁺: 542.3974, found 542.3960.



(3*S*,8*S*,9*S*,10*R*,13*R*,14*S*,17*R*)-17-((2*R*,5*S*,*E*)-5-ethyl-6-methylhept-3-en-2-yl)-10,13dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phe nanthren-3-yl isonicotinate (2F). White solid; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.75 (d, *J* = 5.5 Hz, 2H), 7.83 (d, *J* = 5.5 Hz, 2H), 5.41 (d, *J* = 5.1 Hz, 1H), 5.18 – 5.11(m, 1H), 5.04 – 4.98(m, 1H), 4.91 – 4.83(m, 1H), 2.46 (d, *J* = 7.5 Hz, 2H), 2.10 – 1.85 (comp, 6H), 1.79 – 1.65(m, 2H), 1.59 – 1.43 (comp, 7H), 1.28 – 1.09 (comp, 7H), 1.08 – 0.99 (comp, 8H), 0.86 – 0.78 (comp, 8H), 0.70 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 199.5, 170.8, 165.0, 150.5, 138.1, 124.2, 123.0, 84.1, 53.8, 50.4, 43.1, 38.7, 36.8, 35.8, 35.5, 34.0, 32.8, 31.6, 27.7, 23.7, 20.7, 17.5, 12.4; HRMS (TOF MS ESI⁺) calculated for C₃₅H₅₁NO₂Na [M+Na]⁺: 540.3817, found 540.3833.



(1*S*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl isonicotinate (2G). Colorless oil; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.81 – 8.63 (m, 2H), 7.84 – 7.72 (m, 2H), 4.94 – 4.88 (m, 1H), 2.10 – 2.04 (m, 1H), 1.91 – 1.83 (m, 1H), 1.73 – 1.65 (m, 2H), 1.57 – 1.46 (m, 2H), 1.13 – 1.03 (m, 2H), 0.93 – 0.83 (comp, 7H), 0.74 (d, *J* = 7.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 164.6, 150.6, 138.0, 122.9, 76.0, 47.2, 40.8,

34.2, 31.5, 26.6, 23.6, 22.0, 20.8, 16.5; HRMS (TOF MS ESI⁺) calculated for $C_{16}H_{23}NO_2Na \ [M+Na]^+$: 284.1626, found 284.1620.

General Procedure for the Formal [1+2+2] Cycloaddition.

To a 10-mL oven-dried vial with a magnetic stirring bar, CuCl (1.0 mg, 5.0 mol%) in freshly distilled 1,4-dioxane (1.0 mL), was added a solution of diazo compounds **1** (0.2 mmol) and pyridine **2** (0.3 mmol) in 1,4-dioxane (1.0 mL) *via* a syringe pump at room temperature under argon atmosphere in 1 h. Then the resulting reaction mixture was stirred at 40 $^{\circ}$ C for additional 18 h. After the reaction was completed, the reaction mixture was directly purified by column chromatography on silica gel (eluent: Hexanes: EtOAc = 50:1 to 20:1) to give the pure products **3** in moderate to high yields.



7-Phenyl-6*H***-chromeno[3,4-***b***]indolizine (3a). 44.0 mg, 74% yield. Yellow solid, mp = 166-169°C; ¹H NMR (400 MHz, CDCl₃) (\delta, ppm) 8.50 (d,** *J* **= 7.1 Hz, 1H), 7.80 – 7.62 (m, 2H), 7.51 – 7.47 (m,** *J* **= 7.6 Hz, 2H), 7.43 – 7.37 (m, 2H), 7.36 – 7.29 (m, 1H), 7.16 – 7.09 (comp, 3H), 6,81 – 6.77 (m, 1H), 7.80 – 7.62 (m, 1H), 5.47 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) (\delta, ppm) 153.2, 134.3, 132.1, 129.02, 128.95, 126.6, 126.2, 123.1, 122.1, 120.8, 119.9, 119.6, 118.5, 118.1, 117.6, 116.3, 112.2, 111.4, 65.2; HRMS (TOF MS ESI⁺) calculated for : C₂₁H₁₅NONa [M+Na]⁺: 320.1046, found 230.1044.**



7-(4-Bromophenyl)-6*H***-chromeno[3,4-***b***]indolizine (3b).** 51.0 mg, 68% yield. Yellow solid, mp = 165-166°C; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.50 (d, *J* = 7.1 Hz, 1H), 7.71 – 7.69 (m, 1H), 7.66 – 7.55 (comp, 3H), 7.29 – 7.21 (m, 2H), 7.21 – 7.06 (m, 3H), 6.84 – 6.80 (m, 1H), 6.73 – 6.69 (m, 1H), 5.41 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm)153.2, 133.3, 132.10, 132.08, 130.5, 126.7, 123.3, 122.2, 120.7, 120.1, 119.9, 119.4, 118.5, 118.2, 117.7, 116.6, 112.4, 110.2, 65.0; HRMS (TOF MS ESI⁺) calculated for C₂₁H₁₄BrNONa [M+Na]⁺: 398.0156, found 398.0147.



7-(4-Chlorophenyl)-6*H***-chromeno[3,4-***b***]indolizine (3c). 43.1 mg, 65% yield. Yellow solid, mp = 162-163^{\circ}C; ¹H NMR (400 MHz, CDCl₃) (\delta, ppm) 8.50 (d,** *J* **= 7.1 Hz, 1H), 7.71 – 7.69 (m, 1H), 7.64 – 7.61 (m, 1H), 7.50 – 7.38 (m, 2H), 7.38 – 7.28 (m, 2H), 7.19 – 7.03 (comp, 3H), 6.85 – 6.74 (m, 1H), 6.73 – 6.69 (m, 1H), 5.42 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) (\delta, ppm) 153.2, 132.8, 132.1, 132.0, 130.2, 129.2, 126.8, 123.2, 122.2, 120.7, 119.9, 119.5, 118.5, 118.22, 117.7, 116.5, 112.4, 110.2, 65.0; HRMS (TOF MS ESI⁺) calculated for C₂₁H₁₄ClNNaO [M+Na]⁺: 354.0662, found 354.0670.**



7-(4-Methoxyphenyl)-6*H***-chromeno[3,4-***b***]indolizine (3d). 39.9 mg, 61% yield. Yellow solid, mp = 133-134 °C; ¹H NMR (400 MHz, CDCl₃) (\delta, ppm) 8.48 (d,** *J* **= 7.1 Hz, 1H), 7.71 – 7.69 (m, 1H), 7.63 (d,** *J* **= 8.8 Hz, 1H), 7.34 – 7.29 (m, 2H), 7.16 –** 7.06 (comp, 3H), 7.05 – 6.99 (m, 2H), 6.75 (d, J = 9.1 Hz, 1H), 6.69 – 6.67 (m, 1H), 5.44 (s, 2H), 3.87 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 158.3, 153.2, 132.0, 130.2, 126.7, 126.5, 123.1, 122.1, 120.7, 119.9, 119.7, 118.5, 117.73, 117.65, 116.1, 114.5, 112.1, 111.1, 65.2, 55.5; HRMS (TOF MS ESI⁺) calculated for C₂₂H₁₇NO₂Na [M+Na]⁺: 350.1157, found 350.1155.



7-(2-Methoxyphenyl)-6*H***-chromeno[3,4-***b***]indolizine (3e). 47.1 mg, 72% yield. Yellow solid; ¹H NMR (400 MHz, CDCl₃) (\delta, ppm) 8.50 –8.48 (m, 1H), 7.54 – 7.50 (m, 1H), 7.44 –7.41 (m, 1H), 7.37 – 7.33 (m, 1H), 7.20 – 6.92 (comp, 6H), 6.77 – 6.73 (m, 1H), 6.69 – 6.65 (m, 1H), 5.29 (s, 2H), 3.82 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (\delta, ppm) 156.9, 153.2, 132.6, 131.5, 131.0, 128.2, 126.5, 123.1, 122.7, 122.4, 122.0, 120.9, 119.9, 118.8, 117.7, 117.6, 116.1, 112.0, 111.1, 107.0, 66.2, 55.5; HRMS (TOF MS ESI⁺) calculated for C₂₂H₁₇NO₂Na [M+Na]⁺: 350.1157, found 350.1155.**



7-(4-(Trifluoromethyl)phenyl)-6*H***-chromeno[3,4-***b***]indolizine (3f). 45.3 mg, 62% yield. Yellow solid, mp = 167-168°C; ¹H NMR (400 MHz, CDCl₃) (\delta, ppm) 8.53 (d,** *J* **= 7.1 Hz, 1H), 7.79 – 7.64 (comp, 4H), 7.48 (d,** *J* **= 8.0 Hz, 2H), 7.21 – 7.01 (comp, 3H), 6.89 – 6.78 (m, 1H), 6.76 – 6.72 (m, 1H), 5.44 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) 153.2, 138.2, 132.4, 129.0, 128.2, 127.0, 125.93 (q,** *J* **= 3.8 Hz), 123.4, 122.2, 120.9, 120.0, 119.3, 119.0, 118.1, 117.8, 116.9, 112.6, 110.0, 65.0; ¹⁹F NMR (376 MHz, CDCl₃) (\delta, ppm) -62.25. HRMS (TOF MS ESI⁺) calculated for C₂₂H₁₄F₃NONa [M+Na]⁺: 388.0925, found 388.0920.**



7-(4-Fluorophenyl)-6*H***-chromeno[3,4-***b***]indolizine (3g). 39.7 mg, 63% yield. Yellow solid, mp = 125-126^{\circ}C; ¹H NMR (400 MHz, CDCl₃) (\delta, ppm) 8.49 (d,** *J* **= 7.1 Hz, 1H), 7.71 – 7.69 (m, 1H), 7.61 (d,** *J* **= 9.0 Hz, 1H), 7.38 – 7.28 (m, 2H), 7.22 – 7.05 (comp, 5H), 6.81 – 6.77 (m, 1H), 6.71 – 6.68 (m, 1H), 5.41 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) (\delta, ppm) 161.5 (d,** *J* **= 245.5 Hz), 153.0, 132.0, 130.4, 130.3, 130.13 (d,** *J* **= 3.4 Hz), 126.6, 123.0, 122.0, 120.6, 119.8, 119.4, 118.1 (d,** *J* **= 4.4 Hz), 117.6, 116.2, 115.8 (d,** *J* **= 21.3 Hz), 112.2, 110.2, 64.92; ¹⁹F NMR (376 MHz, CDCl₃) (\delta, ppm) -116.40. HRMS (TOF MS ESI⁺) calculated for C₂₁H₁₄FNONa [M+Na]⁺: 338.0957, found 338.0948.**



7-(3-Fluorophenyl)-*6H***-chromeno**[**3**,**4**-*b*]**indolizine** (**3h**). 34.7 mg, 55% yield. Yellow solid, mp = 129 - 130 °C; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.52 - 8.49 (m, 1H), 7.78 - 7.63 (m, 2H), 7.45 - 7.39 (m, 1H), 7.21 - 7.05 (comp, 5H), 7.05 - 6.98 (m, 1H), 6.88 - 6.79 (m, 1H), 6.75 - 6.65 (m, 1H), 5.44 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 163.3 (d, *J* = 245.7 Hz), 153.2, 136.6 (d, *J* = 8.2 Hz), 132.2, 130.4 (d, *J* = 8.7 Hz), 126.8, 124.7 (d, *J* = 2.6 Hz), 123.3, 122.2, 120.8, 119.9, 119.4, 118.5 (d, *J* = 37.0 Hz), 117.7, 116.6, 115.7, 115.5, 113.0 (d, *J* = 21.2 Hz), 112.4, 110.2, 65.0; ¹⁹F NMR (376 MHz, CDCl₃) (δ , ppm) -112.84. HRMS (TOF MS ESI⁺) calculated for C₂₁H₁₄FNONa [M+Na]⁺: 338.0957, found 338.0955.



7-(2-Fluorophenyl)-6*H***-chromeno[3,4-***b***]indolizine (3i). 38.4 mg, 61% yield. Yellow solid, mp = 94-95 °C; ¹H NMR (400 MHz, CDCl₃) (\delta, ppm) 8.51 (d,** *J* **= 7.1 Hz, 1H), 7.72 – 7.70 (m, 1H), 7.54 – 7.51 (m, 1H), 7.47 – 7.42 (m, 1H), 7.34 – 7.30 (m, 1H), 7.27 – 7.19 (m, 2H), 7.18 – 7.06 (comp, 3H), 6.83 –6.79 (m, 1H), 6.73 – 6.69 (m, 1H), 5.36 (d,** *J* **= 1.4 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) (\delta, ppm) 156.0 (d,** *J* **= 245.5 Hz), 153.2, 132.6, 131.6 (d,** *J* **= 3.7 Hz), 128.4 (d,** *J* **= 8.1 Hz), 126.7, 124.4 (d,** *J* **= 3.6 Hz), 123.2, 122.1, 119.9, 119.6, 118.6 (d,** *J* **= 2.1 Hz), 118.3, 117.7, 116.3, 116.1, 112.3, 104.4, 65.5; ¹⁹F NMR (376 MHz, CDCl₃) (\delta, ppm) -115.59. HRMS (TOF MS ESI⁺) calculated for C₂₁H₁₄FNONa [M+Na]⁺: 338.0957, found 338.0966.**



7-(Naphthalen-1-yl)-6*H***-chromeno[3,4-***b***]indolizine (3j). 43.8 mg, 63% yield. Yellow solid, mp = 94-95 °C; ¹H NMR (400 MHz, CDCl₃) (\delta, ppm) 8.45 (d,** *J* **= 4.8 Hz, 1H), 7.84 – 7.78 (comp, 2H), 7.71 – 7.65 (comp, 2H), 7.48 – 7.38 (comp, 3H), 7.32 (t,** *J* **= 7.6 Hz, 1H), 7.18 – 7.14 (m, 1H), 7.04 – 6.97 (comp, 3H), 6.62 – 6.59 (m, 1H), 5.18 – 5.07 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) (\delta, ppm) 151.9, 133.0, 132.1, 131.6, 130.3, 127.4, 126.5, 125.4, 125.1, 124.8, 124.5, 121.9, 121.1, 120.9, 118.7, 118.6, 117.7, 116.5, 111.0, 108.1, 64.4.; HRMS (TOF MS ESI⁺) calculated for C₂₅H₁₇NONa [M+Na]⁺: 370.1208, found 370.1215.**



7-(Thiophen-2-yl)-6H-chromeno[3,4-b]indolizine (3k). 35.8 mg, 59% yield. Yellow

solid, mp = 96-97°C; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.49 – 8.47 (m, 1H), 7.85 – 7.82 (m, 1H), 7.69 – 7.67 (m, 1H), 7.33 – 7.31 (m, 1H), 7.17 – 7.13 (m, 2H), 7.11 – 7.07 (m, 2H), 7.00 – 6.98 (m, 1H), 6.86 – 6.82 (m, 1H), 6.73 – 6.69 (m, 1H), 5.52 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 153.1, 136.0, 132.4, 127.8, 126.8, 124.5, 123.9, 123.2, 122.1, 120.9, 119.8, 119.3, 118.8, 118.6, 117.7, 116.5, 112.5, 104.4, 65.2; HRMS (TOF MS ESI⁺) calculated for C₁₉H₁₃NOSNa [M+Na]⁺: 326.0616, found 326.0612.



7-Methyl-6*H***-chromeno[3,4-***b***]indolizine (3l). 22.6 mg, 48% yield. Yellow oil; ¹H NMR (400 MHz, CDCl₃) (\delta, ppm) 8.39 – 8.36 (m, 1H), 7.64 – 7.62 (m, 1H), 7.36 – 7.39 (m, 1H), 7.14 – 7.00 (comp, 3H), 6.70 – 6.66 (m, 1H), 6.61 – 6.57 (m, 1H), 5.38 (s, 2H), 2.29 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (\delta, ppm) 152.7, 132.8, 126.1, 122.9, 122.0, 121.7, 119.9, 119.5, 117.7, 117.5, 115.8, 115.1, 111.4, 104.1, 65.1, 29.8; HRMS (TOF MS ESI⁺) calculated for C₁₆H₁₃NONa [M+Na]⁺: 258.0895, found 258.0890.**



6-Benzyl-7-phenyl-6*H***-chromeno[3,4-***b***]indolizine (3m).** 58.9 mg, 76% yield. Yellow oil; ¹H NMR (400 MHz, CDCl₃) (δ, ppm) 8.54 (d, *J* = 6.4 Hz, 1H), 7.76 (d, *J* = 7.7 Hz, 1H), 7.59 (d, *J* = 9.1 Hz, 1H), 7.50 – 7.45 (comp, 4H), 7.37 – 7.33 (m, 1H), 7.26 – 7.16 (comp, 4H), 7.14 – 7.10 (m, 1H), 7.09 – 7.04 (comp, 3H), 6.78 (s, 1H), 6.75 – 6.66 (m, 1H), 5.91 – 5.88 (m, 1H), 3.17 – 3.13 (m, 1H), 2.87 – 2.82(m, 1H); ¹³C NMR (100 MHz, CDCl₃) (δ, ppm) 150.8, 138.1, 134.3, 132.6, 129.42, 129.41, 128.9, 128.3, 126.8, 126.48, 126.46, 124.0, 123.4, 121.8, 119.8, 119.3, 118.9, 118.6, 118.1,

115.4, 112.3, 111.4, 76.7, 41.8; HRMS (TOF MS ESI⁺) calculated for C₂₈H₂₁NONa [M+Na]⁺: 410.1521, found 410.1515.



6-Methyl-7-phenyl-6*H***-chromeno[3,4-***b***]indolizine (3n). 43.0 mg, 69% yield. Yellow solid, mp = 150.5-153.0°C; ¹H NMR (400 MHz, CDCl₃) (\delta, ppm) 8.52 (d, J = 7.1 Hz, 1H), 7.77 – 7.72 (m, 1H), 7.55 (d, J = 8.9 Hz, 1H), 7.52 – 7.45 (comp, 4H), 7.36 – 7.32 (m, 1H), 7.18 – 7.05 (comp, 3H), 6.78 – 6.74 (m, 1H), 6.70 – 6.67 (m, 1H), 5.82 (q, J = 6.5 Hz, 1H), 1.47 (d, J = 6.5 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) (\delta, ppm) 151.2, 134.5, 132.6, 129.6, 128.8, 126.6, 126.5, 125.5, 123.2, 121.7, 119.7, 119.1, 118.5, 118.4, 117.9, 115.1, 112.2, 111.1, 71.9, 21.8; HRMS (TOF MS ESI⁺) calculated for C₂₂H₁₇NONa [M+Na]⁺: 334.1208, found 334.1200.**



1-(7-Phenyl-6*H***-chromeno[3,4-***b***]indolizin-9-yl)ethan-1-one (30).** 52.3 mg, 77% yield. Yellow solid; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.40 – 8.37 (m, 1H), 8.23 – 8.22 (m, 1H), 7.73 – 7.70 (m, 1H), 7.54 – 7.50 (m, 2H), 7.41 – 7.37 (comp, 3H), 7.27 – 7.24 (m, 1H), 7.22 – 7.18 (m, 1H), 7.13 – 7.07 (m, 2H), 5.40 (d, *J* = 1.3 Hz, 2H), 2.54 (d, *J* = 1.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 195.4, 153.9, 133.2, 130.6, 129.3, 129.2, 128.1, 127.2, 126.4, 122.4, 122.3, 122.2, 121.6, 120.8, 119.6, 118.5, 118.0, 117.4, 110.1, 64.8, 25.9; HRMS (TOF MS ESI⁺) calculated for C₂₃H₁₇NO₂Na [M+Na]⁺: 362.1157, found 362.1149.



Methyl 7-phenyl-6*H***-chromeno**[**3**,**4**-*b*]**indolizine-9-carboxylate** (**3p**). 51.2 mg, 72% yield. Yellow solid, mp = 129-130°C; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.41 – 8.37 (m, 2H), 7.72 – 7.70(m, 1H), 7.52 – 7.48 (m, 2H), 7.39 – 7.37 (comp, 3H), 7.25 – 7.20 (m, 2H), 7.12 – 7.07 (m, 2H), 5.41 (s, 2H), 3.89 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 166.3, 153.8, 133.2, 131.0, 129.3, 129.2, 127.9, 127.0, 122.3, 122.21, 122.17, 122.0, 120.7, 119.1, 118.71, 118.67, 118.0, 116.5, 111.4, 64.9, 52.2; HRMS (TOF MS ESI⁺) calculated for C₂₃H₁₇NO₃Na [M+Na]⁺: 378.1106, found 378.1100.



7-Phenyl-6*H***-chromeno[3,4-***b***]indolizine-9-carbonitrile (3q). 42.6 mg, 66% yield. Yellow solid, mp = 142-143 °C; ¹H NMR (400 MHz, CDCl₃) (δ, ppm) 8.46 (d,** *J* **= 7.4 Hz, 1H), 8.02 – 8.01(m, 1H), 7.72 – 7.70 (m, 1H), 7.55 – 7.48 (m, 2H), 7.43 – 7.39 (m, 1H), 7.38 – 7.34 (m, 2H), 7.24 – 7.22 (m, 1H), 7.17 – 7.07 (m, 2H), 6.78 – 6.75(m, 1H), 5.43 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) (δ, ppm) 154.0, 132.5, 130.1, 129.3, 129.2, 128.6, 127.6, 125.7, 122.9, 122.8, 122.4, 120.8, 120.1, 118.2, 118.1, 116.7, 111.9, 99.3, 64.7; HRMS (TOF MS ESI⁺) calculated for C₂₂H₁₄N₂ONa [M+Na]⁺: 345.1004, found 345.1008.**



8,10-Dimethyl-7-phenyl-6*H***-chromeno[3,4-***b***]indolizine (3r). 44.2 mg, 68% yield. Yellow solid, mp = 70-71 °C; ¹H NMR (400 MHz, CDCl₃) (\delta, ppm) 8.23 (s, 1H), 7.76 – 7.73 (m, 1H), 7.42 – 7.31 (comp, 5H), 7.14 – 7.05 (comp, 3H), 6.40 (d,** *J* **= 1.4 Hz, 1H), 5.20 (s, 2H), 2.30 (d,** *J* **= 1.2 Hz, 3H), 2.07 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (\delta, ppm)153.1, 135.7, 131.3, 130.6, 129.0, 127.6, 126.7, 126.3, 122.0, 121.9, 121.7, 120.8, 120.0, 119.9, 118.9, 117.6, 115.2, 112.2, 65.2, 20.7, 18.6; HRMS (TOF MS ESI⁺) calculated for C₂₃H₁₉NONa [M+Na]⁺:348.1364, found 348.1358.**



8-Methyl-7-phenyl-6*H*-chromeno[3,4-*b*]indolizine (3s) and 10-Methyl-7-phenyl-6*H*-chromeno[3,4-*b*]indolizine (3s'). Combined in 63% yield, 39.2 mg (3s : 3s' = 6 : 1). Green oil; composited NMR signals of 3s and 3s'; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.43 (d, J = 7.1 Hz, 1H), 8.30 (d, J = 0.9 Hz, 0.19H), 7.76 – 7.71 (m, 1H), 7.63 (d, J = 9.1 Hz, 0.19H), 7.49 (t, J = 7.6 Hz, 1H), 7.44 – 7.31 (comp, 5.55H), 7.16 – 7.08 (comp, 3.54H), 6.69 – 6.66(m, 0.19H), 6.61 (t, J = 6.9 Hz, 1H), 6.51 (d, J = 6.7 Hz, 1H), 5.46 (s, 0.36H), 5.23 (s, 2H), 2.35 (s, 0.55H), 2.10 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 153.2, 135.6, 134.5, 131.6, 131.4, 131.1, 129.7, 128.94, 128.91, 127.6, 126.8, 126.43, 126.37, 126.0, 122.2, 122.0, 121.6, 121.4, 121.2, 120.8, 120.3, 119.9, 119.8, 119.7, 118.5, 117.8, 117.63, 117.59, 116.0, 115.5, 112.4, 111.5, 65.2, 65.1, 22.8, 20.9; HRMS (TOF MS ESI⁺) calculated for C₂₂H₁₇NONa [M+Na]⁺: 334.1208, found 334.1218.



8-Ethyl-7-phenyl-6*H*-chromeno[3,4-*b*]indolizine (3t) and 10-Ethyl-7-phenyl-6*H*-chromeno[3,4-*b*]indolizine (3t'). Combined in 65% yield, 42.3 mg (3t : 3t' = 4 : 1). Green oil; composited NMR signals of 3t and 3t'; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.44 (d, J = 7.0 Hz, 1H), 8.32 (s, 0.17H), 7.78 – 7.73(comp, 1.33H), 7.59 – 7.54(m, 0.18H), 7.50 – 7.33 (comp, 1.81H), 7.29 – 7.26(m, 1H), 7.16 – 6.69 (comp, 8.36H), 6.69 – 6.60 (comp, 1.18H), 6.53 (s, 1H), 5.31 – 5.13 (comp, 2.34H), 3.85 (s, 0.52H), 3.81 (s, 3.00H), 2.36 (s, 0.52H), 2.11 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 153.2, 153.1, 135.9, 134.5, 131.3, 131.1, 131.0, 129.0, 128.9, 128.0, 127.8, 126.9, 126.42, 126.38, 126.0, 122.3, 122.1, 122.0, 121.2, 120.5, 120.4, 120.1, 119.90, 119.88, 119.8, 119.7, 118.1, 117.7, 116.4, 116.1, 115.6, 112.0, 111.6, 111.1, 65.22, 65.15, 26.5, 25.9, 15.3, 13.9; HRMS (TOF MS ESI⁺) calculated for C₂₄H₁₉NONa [M+Na]⁺: 348.1364, found 348.1378.



7-(2-Methoxyphenyl)-8-methyl-6*H*-chromeno[3,4-*b*]indolizine (3u) and 7-(2-Methoxyphenyl)-10-methyl-6*H*-chromeno[3,4-*b*]indolizine (3u'). Combined in 50% yield, 34.1 mg (3u : 3u' = 6 : 1). Green oil; composited NMR signals of 3y and 3y'; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.44 (d, J = 7.0 Hz, 1H), 8.32 (s, 0.17H), 7.78 – 7.73(comp, 1.33H), 7.59 – 7.54(m, 0.18H), 7.50 – 7.33 (comp, 1.81H), 7.29 – 7.26(m, 1H), 7.16 – 6.69 (comp, 8.36H), 6.69 – 6.60 (comp, 1.18H), 6.53 (s, 1H), 5.31 - 5.13 (comp, 2.34H), 3.85 (s, 0.52H), 3.81 (s, 3.00H), 2.36 (s, 0.52H), 2.11 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 158.0, 153.1, 133.5, 132.1, 131.6, 131.5, 131.0, 129.8, 128.9, 128.7, 128.1, 126.3, 124.9, 124.1, 122.7, 121.9, 121.4, 120.9, 120,0 119.9, 119.8, 118.3, 118.3, 118.2, 117.5, 115.7, 111.4, 111.1, 110.5, 107.5, 68.3, 66.2, 65.5, 55.5, 29.8, 20.0; HRMS (TOF MS ESI⁺) calculated for C₂₃H₁₉NO₂Na [M+Na]⁺: 364.1313, found 364.1306.



7-Phenyl-6*H***-chromeno[3',4':4,5]pyrrolo[2,1-***a***]isoquinoline (3v**). 50.0 mg, 72% yield. Yellow solid, mp = 120-121 °C; ¹H NMR (400 MHz, CDCl₃) (δ, ppm) 8.36 (d, *J* = 7.5 Hz, 1H), 7.76 – 7.71 (m, 2H), 7.57 – 7.55 (m, 1H), 7.52 – 7.41 (comp, 5H), 7.32 – 7.28 (m, 1H), 7.20 – 7.14 (m, 2H), 7.12 – 7.07 (m, 2H), 6.88 (d, *J* = 7.5 Hz, 1H), 5.21 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) (δ, ppm) 153.6, 135.6, 130.5, 129.0, 127.5, 127.4, 127.2, 127.1, 126.98, 126.96, 125.8, 122.9, 122.5, 122.1, 120.9, 120.3, 119.4, 118.1, 117.9, 115.5, 112.1, 65.0; HRMS (TOF MS ESI⁺) calculated for C₂₅H₁₇NONa [M+Na]⁺: 370.1208, found 370.1200.



Methyl 11-bromo-7-phenyl-6,7a-dihydro-14a*H*-chromeno[3',4':4,5]pyrrolo[2,1-*a*] isoquinoline-14a-carboxylate (3w). 74.9 mg, 77% yield. Yellow solid, mp = $138-139^{\circ}$ C; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.47 – 7.38 (comp, 4H), 7.32 – 7.23 (comp, 4H), 7.03 – 6.93 (comp, 3H), 6.61 (t, *J* = 7.8 Hz, 1H), 6.36 (d, *J* = 7.6 Hz, 1H), 6.11 (d, *J* = 7.6 Hz, 1H), 5.91 (d, *J* = 2.8 Hz, 1H), 5.08 – 4.94 (m, 2H), 3.83 (s, 3H);

¹³C NMR (100 MHz, CDCl₃) (δ, ppm) 171.1, 154.3, 138.3, 134.3, 133.6, 133.2, 131.2, 130.7, 130.0, 129.1, 128.7, 128.2, 126.7, 125.9, 123.5, 123.3, 121.5, 119.1, 118.0, 102.5, 72.0, 69.3, 62.6, 53.4; HRMS (TOF MS ESI⁺) calculated for C₂₇H₂₀BrNO₃Na [M+Na]⁺: 508.0524, found 508.0511.



Methyl 10-bromo-7-phenyl-6,7a-dihydro-14a*H*-chromeno[3',4':4,5]pyrrolo[2,1-*a*] isoquinoline-14a-carboxylate (3x). 71.0 mg, 73% yield. Yellow solid, mp = 135-136°C; ¹H NMR (400 MHz, CDCl₃) 7.44 – 7.34 (comp, 4H), 7.27 – 7.19 (comp, 3H), 7.09 (d, J = 2.1 Hz, 1H), 6.95 – 6.89 (comp, 3H), 6.85 – 6.82 (m, 1H), 6.20 (d, J = 8.2 Hz, 1H), 5.84 (d, J = 2.8 Hz, 1H), 5.64 (d, J = 7.4 Hz, 1H), 5.03 – 4.90 (m, 2H), 3.79 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 171.2, 154.3, 138.5, 136.0, 133.7, 133.6, 130.5, 130.0, 129.1, 128.7, 128.2, 127.6, 127.0, 126.7, 126.0, 125.9, 123.3, 121.4, 121.2, 118.1, 72.1, 68.7, 62.6, 53.3; HRMS (TOF MS ESI⁺) calculated for C₂₇H₂₀BrNO₃Na [M+Na]⁺: 508.0524, found 508.0526.



7-Phenyl-8,9,10,11-tetrahydro-6*H***-chromeno[3',4':4,5]pyrrolo[2,1-***a***]isoquinoline (3y**). 35.1 mg, 50% yield. Yellow solid, mp = 122-123 °C; ¹H NMR (400 MHz, CDCl₃) (δ, ppm) 8.32 (s, 1H), 7.67 (d, *J* = 6.9 Hz, 1H), 7.43 – 7.28 (comp, 5H), 7.09 – 7.03 (comp, 3H), 6.41 (d, *J* = 7.1 Hz, 1H), 5.17 (s, 2H), 2.68 (s, 2H), 2.34 (t, *J* = 6.3 Hz, 2H), 1.79 –1.73 (m, 2H), 1.65 – 1.57 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) (δ, ppm) 153.0, 136.1, 134.5, 131.4, 131.3, 127.6, 127.4, 126.6, 126.1, 122.2, 122.0, 120.9, 119.8, 119.7, 117.6, 114.3, 111.3, 65.2, 29.1, 27.5, 22.8, 22.6; HRMS (TOF MS ESI⁺) calculated for C₂₅H₂₂NO [M+H]⁺: 352.1701, found 352.1710.



(3*S*,8*R*,9*S*,10*R*,13*S*,14*S*)-10,13-Dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17 -tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl 7-phenyl-6*H*-chromeno[3,4-*b*] indolizine-9-carboxylate (3A). 77.0 mg, 63% yield. Yellow solid, mp =145-146 °C; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.42 (d, *J* = 7.5 Hz, 1H), 8.39 (d, *J* = 1.8 Hz, 1H), 7.74 – 7.72 (m, 1H), 7.53 – 7.49 (comp, 2H), 7.43 – 7.35 (comp, 3H), 7.27 – 7.22 (m, 1H), 7.22 – 7.18 (m, 1H), 7.16 – 7.04 (m, 2H), 5.43 (s, 2H), 4.91 – 4.78 (m, 1H), 2.52 – 2.43 (m, 2H), 2.19 – 2.00 (comp, 3H), 1.97 – 1.81 (comp, 3H), 1.72 – 1.64 (comp, 3H), 1.55 – 1.41 (m, 2H), 1.39 – 1.21 (comp, 7H), 1.09 (s, 3H), 0.89 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 165.3, 153.8, 140.1, 133.3, 131.0, 129.2, 129.1, 127.8, 127.0, 122.3, 122.2, 122.1, 122.0, 121.9, 120.6, 119.3, 119.0, 118.7, 118.0, 116.3, 111.5, 74.6, 64.9, 51.8, 50.2, 47.6, 38.3, 37.1, 36.9, 35.9, 31.6, 31.5, 30.9, 27.9, 22.0, 20.5, 19.5, 13.7; HRMS (TOF MS ESI⁺) calculated for C₄₁H₄₁NO₄Na [M+Na]⁺: 634.2933, found 634.2950.

S26



(3*S*,5*S*,8*R*,9*S*,10*S*,13*S*,14*S*)-10,13-Dimethyl-17-oxohexadecahydro-1*H*-cyclopenta[a]phenanthren-3-yl 7-phenyl-6*H*-chromeno[3,4-*b*]indolizine-9-carboxylate (3B). 68.7 mg, 56% yield. Yellow solid, mp =93-94 °C; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.44 (d, *J* = 7.4 Hz, 1H), 8.38 (d, *J* = 1.9 Hz, 1H), 7.75 – 7.73 (m, 1H), 7.53 – 7.49 (m, 2H), 7.42 – 7.36 (comp, 3H), 7.25 (d, *J* = 6.4 Hz, 1H), 7.22 – 7.18 (m, 1H), 7.16 – 7.08 (m, 2H), 5.44 (s, 2H), 4.89 – 4.80 (m, 1H), 2.52 – 2.43 (m, 1H), 2.13 – 2.02 (m, 1H), 1.98–1.90 (m, 2H), 1.82 – 1.76 (comp, 3H), 1.73 – 1.62 (comp, 3H), 1.61 – 1.45 (comp, 4H), 1.36 – 1.32 (m, 2H), 1.25 (s, 3H), 1.16 – 1.07 (m, 1H), 1.06 – 0.97 (m, 1H), 0.90 (s, 3H), 0.87 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 165.5, 153.8, 133.4, 131.1, 129.3, 129.2, 127.9, 127.0, 122.3, 122.2, 122.0, 121.9, 120.6, 119.5, 119.0, 118.8, 118.0, 116.3, 111.5, 74.4, 64.9, 54.5, 51.5, 47.9, 44.9, 36.9, 36.0, 35.9, 35.2, 34.2, 31.7, 31.0, 28.5, 27.7, 21.9, 20.6, 14.0, 12.5; HRMS (TOF MS ESI⁺) calculated for C₄₁H₄₃NO₄Na [M+Na]⁺: 636.3090, found 636.3084.



(8*R*,9*S*,10*R*,13*S*,14*S*,17*S*)-10,13-Dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17 -tetradecahydro-1*H*-cyclopenta[a]phenanthren-17-yl 7-phenyl-6*H*-chromeno [3,4-*b*]indolizine-9-carboxylate (3C). 74.6 mg, 61% yield. Yellow solid, mp = 99-100 °C; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.50 – 8.38 (m, 2H), 7.76 – 7.74 (m, 1H), 7.51 (t, *J* = 7.6 Hz, 2H), 7.44 – 7.36 (comp, 3H), 7.26 – 7.18 (m, 2H), 7.16 – 7.08 (m, 2H), 5.75 (d, *J* = 1.6 Hz, 1H), 5.45 (s, 2H), 4.87–4.83 (m, 1H), 2.43 – 2.36 (comp, 3H), 2.33 – 2.18 (comp, 3H), 2.05 – 2.00 (m, 1H), 1.91 – 1.86 (m, 2H), 1.75 –1.65 (comp, 3H), 1.64 – 1.57 (m, 2H), 1.46 – 1.39 (m, 2H), 1.31 – 1.23 (comp, 3H), 1.21 (s, 3H), 0.98 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 199.6, 171.1, 165.7, 153.8, 133.3, 131.0, 129.13, 129.14, 127.9, 127.0, 124.1, 122.3, 122.2, 122.0, 120.6, 119.2, 119.1, 118.7, 118.0, 116.4, 111.4, 83.1, 64.9, 53.8, 50.4, 43.0, 38.7, 36.9, 35.8, 35.5, 34.0, 32.9, 31.6, 27.9, 23.7, 20.7, 17.5, 12.4; HRMS (TOF MS ESI⁺) calculated for C₄₁H₄₁NO₄Na [M+Na]⁺: 634.2933, found 634.2930.



(35,85,95,10*R*,13*R*,145,17*R*)-10,13-Dimethyl-17-((*R*)-6-methylheptan-2-yl)-2,3,4,7 ,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl 7-phenyl-6*H*-chromeno[3,4-*b*]indolizine-9-carboxylate (3D). 82.4 mg, 58% yield. Yellow solid, mp = 164-165 °C; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.40 – 8.37 (m, 2H), 7.70 (d, *J* = 7.5 Hz, 1H), 7.50 (t, *J* = 7.6 Hz, 2H), 7.40 – 7.34 (comp, 3H), 7.24 – 7.22 (m, 1H), 7.20 – 7.15 (m, 1H), 7.11 – 7.06 (m, 2H), 5.41 (s, 2H), 4.86 – 4.80 (m, 1H), 2.45 (d, *J* = 7.3 Hz, 2H), 2.03 – 1.94 (comp, 3H), 1.92 – 1.87 (m, 1H), 1.74 – 1.66 (m, 1H), 1.61 – 1.39 (comp, 6H), 1.38 – 1.29 (comp, 4H), 1.29 – 1.22 (m, 3H), 1.16 – 1.10 (comp, 5H), 1.07 – 1.05 (comp, 4H), 1.02 – 0.95 (comp, 3H), 0.91 (d, *J* = 6.5 Hz, 3H), 0.88 – 0.86 (comp, 6H), 0.68 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 165.3, 153.8, 139.8, 133.3, 131.0, 129.2, 129.1, 127.8, 126.9, 122.9, 122.2, 122.1, 122.0, 121.8, 120.6, 119.5, 118.9, 118.7, 117.9, 116.3, 111.5, 74.8, 64.9, 56.8, 56.3, 50.2, 42.4, 39.9, 39.6, 38.4, 36.8, 36.3, 35.9, 32.1, 32.0, 28.4, 28.1, 28.0, 24.4, 24.0, 23.0, 22.7, 21.2, 19.5, 18.8, 12.0; HRMS (TOF MS ESI⁺) calculated for C₄₉H₆₀NO₃[M+H]⁺: 710.4573, found 710.4571.



(35,85,95,10*R*,13*R*,14*S*,17*R*)-17-((2*R*,5*R*)-5-Ethyl-6-methylheptan-2-yl)-10,13-dim ethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenan thren-3-yl 7-phenyl-6*H*-chromeno[3,4-*b*]indolizine-9-carboxylate (3E). 80.0 mg, 54% yield. Yellow solid, mp =85-86 °C; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.44 (d, *J* = 7.5 Hz, 1H), 8.40–8.38 (m, 1H), 7.74 (d, *J* = 7.6 Hz, 1H), 7.52 (t, *J* = 7.6 Hz, 2H), 7.44 – 7.36 (comp, 3H), 7.27 – 7.24 (m, 2H), 7.23 – 7.18 (m, 1H), 7.16 – 7.08 (m, 2H), 5.43 (d, *J* = 4.9 Hz, 2H), 4.89–4.81 (m, 1H), 2.47 (d, *J* = 7.5 Hz, 1H), 2.05 – 1.96 (comp, 3H), 1.87 – 1.67 (comp, 4H), 1.38 – 1.21 (comp, 10H), 1.15 – 0.99 (comp, 10H), 0.96 –0.91(comp, 6H), 0.87–0.77 (comp, 11H), 0.69 (d, *J* = 5.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 165.3, 153.9, 139.8, 133.4, 131.1, 129.3, 129.2, 127.8, 127.0, 122.9, 122.3, 122.2, 122.1, 121.9, 120.6, 119.5, 119.0, 118.8, 118.0, 116.3, 111.5, 74.9, 64.9, 56.8, 56.2, 50.2, 46.0, 42.5, 39.9, 38.4, 37.2, 36.8, 36.3, 34.1, 32.1, 32.0, 29.3, 28.4, 28.1, 26.2, 24.5, 23.2, 21.2, 20.0, 19.6, 19.2, 18.9, 12.1, 12.0; HRMS (TOF MS ESI⁺) calculated for C₅₁H₆₃NO₃Na [M+Na]⁺: 760.4706, found 760.4700.



(35,85,95,10*R*,13*R*,145,17*R*)-17-((2*R*,55,*E*)-5-Ethyl-6-methylhept-3-en-2-yl)-10,13 -dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]ph enanthren-3-yl 7-phenyl-6*H*-chromeno[3,4-*b*]indolizine-9-carboxylate (3F). 86.9 mg, 59% yield. Yellow solid, mp = 101-102 °C; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.44 (d, *J* = 7.5 Hz, 1H), 8.40 (d, *J* = 1.8 Hz, 1H), 7.76 – 7.73 (m, 1H), 7.52 (t, *J* = 7.6 Hz, 2H), 7.44 – 7.35 (comp, 3H), 7.28 – 7.24 (m, 2H), 7.22 – 7.18 (m, 1H), 7.16 – 7.08 (m, 2H), 5.44 (s, 2H), 5.19 –5.13(m, 1H), 5.05 – 4.99(m, 1H), 4.88 – 4.82(m, 1H), 2.47 (d, *J* = 8.0 Hz, 2H), 1.98 (comp, 5H), 1.72 (comp, 3H), 1.59 – 1.42 (comp, 8H), 1.33 – 1.16 (comp, 7H), 1.10 – 1.01 (comp, 7H), 0.87 – 0.79 (comp, 9H), 0.71 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 165.4, 153.8, 139.9, 138.5, 133.4, 131.1, 129.4, 129.3, 129.2, 127.9, 127.0, 122.9, 122.3, 122.2, 122.1, 121.9, 120.6, 119.5, 119.0, 118.8, 118.0, 116.4, 111.6, 74.9, 65.0, 57.0, 56.1, 51.4, 50.2, 42.4, 40.7, 39.8, 38.4, 37.2, 36.8, 32.1, 32.0, 29.1, 28.1, 25.6, 24.5, 21.4, 21.3, 21.2, 19.6, 19.2, 12.4, 12.2; HRMS (TOF MS ESI⁺) calculated for C₅₁H₆₁NO₃Na [M+Na]⁺: 758.4549, found 758.4540.



(1*S*,2*S*,5*R*)-2-Isopropyl-5-methylcyclohexyl 7-phenyl-6*H*-chromeno[3,4-*b*] indolizine-9-carboxylate (3G). 59.5 mg, 62% yield. Yellow solid, mp =85-86 °C; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.44 – 8.41 (m, 2H), 7.74 – 7.71 (m, 1H), 7.50 (t, *J* = 7.6 Hz, 2H), 7.41 – 7.34 (comp, 3H), 7.26 – 7.24 (m, 1H), 7.21 – 7.17 (m, 1H), 7.13 – 7.07 (m, 2H), 5.43 (d, *J* = 1.2 Hz, 2H), 4.92 (td, *J* = 10.9, 4.5 Hz, 1H), 2.17 – 2.08 (m, 1H), 1.98 – 1.93 (m, 1H), 1.75 – 1.70 (m, 2H), 1.58 – 1.51 (m, 2H), 1.28 – 1.24 (m, 1H), 1.17 – 1.06 (m, 2H), 0.93 (d, *J* = 6.8 Hz, 6H), 0.83 (d, *J* = 6.9 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 165.4, 153.8, 133.4, 131.1, 129.2, 129.1, 127.8, 127.0, 122.3, 122.14, 122.12, 121.9, 120.6, 119.5, 118.9, 118.8, 118.0, 116.3, 111.5, 75.1, 64.9, 47.4, 41.2, 34.5, 31.6, 27.0, 24.1, 22.2, 20.8, 17.0; HRMS (TOF MS ESI⁺) calculated for C₃₂H₃₃NO₃Na [M+Na]⁺: 502.2358, found 502.2355.

1D-NOE NMR Analysis:



Figure S1. Proton NMR spectra of mixture of 3y and 3y'.



Figure S2. NOE NMR spectra of 3y and 3y'.



To a 10-mL oven-dried vial with a magnetic stirring bar, CuCl (1.0 mg, 5.0 mol%) and *N*,*N*-dimethylaniline (72.6 mg, 0.6 mmol) in freshly distilled 1,4-dioxane (1.0 mL), was added the solution of diazo **1a** (0.2 mmol) in 1,4-dioxane (1.0 mL) *via* a syringe in 1 hour at room temperature. The reaction mixture was heated at 40 °C under argon atmosphere for 18 h, After the reaction was completed, the solvent was evaporated in *vacuo*, then the crude mixture was purified by column chromatography to give product **4** as white solid, 70% yield, mp = 133.4-136.0 °C; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.50 – 7.44 (comp, 2H), 7.38 – 7.32 (comp, 3H), 7.29 – 7.24 (comp, 3H), 7.09 (d, *J* = 7.7 Hz, 2H), 6.96 (t, *J* = 7.4 Hz, 1H), 6.77 (d, *J* = 7.9 Hz, 2H), 5.28 (s, 1H), 4.95 (s, 2H), 3.75 (s, 3H), 2.97 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 174.0, 155.4, 131.9, 130.0, 129.5, 129.4, 128.8, 128.4, 128.3, 122.5, 121.5, 113.0, 112.3, 87.1, 57.3, 52.3, 50.4, 40.9; HRMS (TOF MS ESI⁺) calculated for C₂₆H₂₅NO₃Na [M+Na]⁺: 422.1727, found 422.1715.



To a 10-mL oven-dried vial with a magnetic stirring bar, CuCl (1.0 mg, 5.0 mol%) and diphenyl sulfoxide (404 mg, 2.0 mmol) in freshly distilled 1,4-dioxane (1.0 mL), was added the solution of diazo **1a** (0.2 mmol) in 1,4-dioxane (1.0 mL) *via* a syringe in 1 hour at room temperature. The reaction mixture was heated at 40°C under argon atmosphere for 18 h, After the reaction was completed, the solvent was evaporated in

vacuo, then the crude mixture was purified by column chromatography to give product **5** as yellow oil, 80% yield; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.92 – 7.90 (m, 1H), 7.66 – 7.55 (m, 1H), 7.47 – 7.42 (comp, 2H), 7.38 – 7.29 (comp, 3H), 7.16 – 7.12 (comp, 2H), 4.96 (s, 2H), 3.94 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 186.4, 165.7, 158.7, 136.3, 131.9, 131.1, 129.2, 128.6, 123.6, 122.2, 122.0, 113.4, 88.2, 82.6, 58.0, 52.7; HRMS (TOF MS ESI⁺) calculated for C₁₈H₁₄O₄Na [M+Na]⁺: 317.0784, found 317.0780.

Control experiment in the presence of dimethyl but-2-ynedioate.



To a 10-mL oven-dried vial with a magnetic stirring bar, CuCl (1.0 mg, 5.0 mol%) and dimethyl but-2-ynedioate (142.1 mg, 1.0 mmol) in freshly distilled 1,4-dioxane (1.0 mL), was added the solution of diazo **1a** (0.2 mmol) and pyridine **2a** (0.3 mmol) in 1,4-dioxane (1.0 mL) *via* a syringe in 1 hour at room temperature. The reaction mixture was heated at 40 °C under argon atmosphere for 18 h, After the reaction was completed, the solvent was evaporated in *vacuo*, then the crude mixture was purified by column chromatography to give product **7** as white solid, 40% yield; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 9.44 (d, *J* = 7.2 Hz, 1H), 7.53 – 7.47 (m, 1H), 7.41 – 7.34 (comp, 4H), 7.32 – 7.28 (comp, 3H), 7.24 (d, *J* = 7.6 Hz, 1H), 7.11 – 7.01 (comp, 2H), 6.91 – 6.87 (m, 1H), 4.83 (s, 2H), 3.90 (s, 3H), 3.82 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 167.0, 161.2, 155.3, 135.0, 132.0, 131.8, 128.9, 128.8, 128.4, 127.5, 127.4, 122.8, 122.5, 122.2, 121.7, 119.4, 114.4, 113.5, 111.7, 111.1, 87.3, 84.2, 56.8, 52.5, 51.7.





To a 10-mL oven-dried vial with a magnetic stirring bar, CuCl (1.0 mg, 5.0 mol%) in freshly distilled 1,4-dioxane (1.0 mL), was added the solution of diazo compound **1a** (61.2 mg, 0.2 mmol) and isoquinoline (38.7 mg, 0.3 mmol) in 1,4-dioxane (1.0 mL) *via* a syringe in 1 hour at room temperature under argon atmosphere. The reaction mixture was heated at 40°C for corresponding period of time (1.0 h, 1.5 h, 24.0 h), then the reaction mixture (0.25 mL) was filtered and the filtrate was evaporated in *vacuo* and the residue was directly subjected to proton NMR analysis with CDCl₃ as the solvent without any further purification. See Figure S3 for these spectra.

Discussion: From this study, the compound **9** is confirmed as the intermediate in this transformation.



Figure S3. Proton NMR spectra monitoring of the reaction mixture.
General Procedure for Scale up



To a 50-mL oven-dried round-bottom flask with a magnetic stirring bar, diazo compound **1a** (2.45 g, 8.0 mmol), pyridine (0.95 g, 12.0 mmol), CuCl (39.6 mg, 5.0 mol%), and anhydrous 1,4-dioxane (30.0 mL) was added in sequence under atmosphere of argon, and the reaction mixture was stirred at 40 °C for 24 hours. When the reaction was completed (monitored by TLC), the most of the solvent was evaporated in *vacuo*, the reaction mixture was purified by flash column chromatography on silica gel (Hexanes : EtOAc = 50:1 to 20:1) to give 1.43 g pure **3a** (60% yield).

Derivatizations:

Procedure for the Preparation of 10.¹



To a 10-mL oven-dried round-bottom flask with a magnetic stirring bar, **3a** (29.7 mg, 0.1 mmol), H₂O₂ (2.0 mmol, 10.0 equiv.), and CH₃CH₂OH (2.0 mL) were added in sequence. Then the reaction mixture was stirred at 60°C for 12 hours. After the reaction completed, the reaction mixture was quenched with saturated brine (10.0 mL) and extracted with EtOAc (3×10.0 mL) The organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure after filtration. The obtained residue was purified by flash column chromatography on silica gel (hexanes : EtOAc = 15:1 to 8:1) to give 21.4 mg pure product **10** as white solid, 65% yield, mp = 90.4 - 90.5 °C; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.45 – 8.32 (m, 1H), 7.78 – 7.62

(comp, 5H), 7.52 - 7.48 (m, 1H), 7.43 - 7.33 (comp, 3H), 7.16 - 7.12 (m, 1H), 7.02 (t, J = 7.9 Hz, 2H), 4.63 (d, J = 12.0 Hz, 1H), 4.03 (d, J = 11.9 Hz, 1H); 13 C NMR (100 MHz, CDCl₃) (δ , ppm) 187.3, 161.5, 156.0, 148.6, 136.7, 136.5, 135.2, 128.9, 128.6, 127.6, 127.4, 123.0, 122.8, 122.3, 122.0, 118.3, 74.3, 68.2, 65.2; HRMS (TOF MS ESI⁺) calculated for C₂₁H₁₅NO₃Na [M+Na]⁺: 352.0950, found 352.0944.

Procedure for the Preparation of 11.²



To a 10-mL oven-dried vial with a magnetic stirring bar, **3a** (29.7 mg, 0.1 mmol), DDQ (0.2 mmol, 2.0 equiv.), and anhydrous C₂H₅OH (2.0 mL) were added in sequence, and the reaction mixture was stirred for 2 hours at room temperature. When the reaction was completed (monitored by TLC), the crude reaction mixture was purified by flash column chromatography on silica gel (Hexanes : EtOAc = 50:1) to give 28.6 mg pure product **11** as yellow solid, 84% yield, mp = 122.4 -122.5 °C; ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 8.58 (d, *J* = 7.2 Hz, 1H), 7.88 – 7.82 (m, 1H), 7.77 – 7.74 (m, 1H), 7.70 – 7.62 (m, 2H), 7.51 (t, *J* = 7.7 Hz, 2H), 7.38 – 7.33 (m, 1H), 7.28 – 7.14 (comp, 3H), 6.84 – 6.80(m, 1H), 6.74 – 6.71 (m, 1H), 4.11 – 4.03 (m, 1H), 3.97 – 3.81 (m, 1H), 1.29 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 145.0, 134.2, 132.2, 131.9, 129.3, 128.9, 126.6, 126.4, 123.7, 122.2, 120.3, 119.9, 119.1, 118.5, 118.4, 118.3, 112.5, 111.6, 95.8, 64.0, 15.41; HRMS (TOF MS ESI⁺) calculated for C₂₃H₁₉NO₂Na [M+Na]⁺: 364.1313, found 364.1310.

References:

Y. He, X. Zhang, L. Cui, J. Wang and X. Fan, *Green Chem.*, **2012**, *14*, 3429.
F. Yang, Y. Li, P. E. Floreancig, X. Li and L. Liu, *Org. Biomol. Chem.*, **2018**, *16*, 5144.
















































































Crystallographic Data for Compound 3a



Bond precision: C-C = 0.0020 A

Wavelength=0.71073

Cell:	a=9.4156(5)	b=14.0062(6)	c=11.1540(6)		
	alpha=90	beta=104.097(2) gamma=90		
Temperature:	120 K				
	Calculated	Repo	orted		
Volume	1426.66(12)	1426.66(12)			
Space group	P 21/c	P 21/c			
Hall group	-P 2ybc	-P 2	2ybc		
Moiety formula	C21 H15 N O	?			
Sum formula	C21 H15 N O	C21 H15 N O			
Mr	297.34	297.34			
Dx,g cm-3	1.384	1.38	34		
Z	4	4			
Mu (mm-1)	0.085	0.08	35		
F000	624.0	624.0			
F000'	624.25				
h,k,lmax	12,18,14	12,1	18,14		
Nref	3278	3268	3		
Tmin,Tmax	0.985,0.990	0.55	59,0.746		
Tmin'	0.983				
Correction meth	od= # Reported T	Limits: Tmin=0	.559 Tmax=0.746		
AbsCorr = MULTI	-SCAN				
Data completeness= 0.997		Theta(max) =	Theta(max) = 27.511		
R(reflections) = 0.0402(2589) wR2(reflections) = 0.100					

S = 1.038 Npar= 208

Crystallographic Data for Compound 9





Bond precision: C-C = 0.0027 A

Wavelength=0.71073

Cell:	a=13.6852(16) b=7.22	65 (6)	c=32.525(3)		
	alpha=90	beta=9	0	gamma=90		
Temperature:	120 K					
	Calculated		Reported			
Volume	3216.6(5)		3216.6(5)			
Space group	Pbca		Pbca			
Hall group	-P 2ac 2ab		-P 2ac 2ab)		
Moiety formula	C21 H15 N O3		C21 H15 N	03		
Sum formula	C21 H15 N O3		C21 H15 N	03		
Mr	329.34		329.34			
Dx,g cm-3	1.360		1.360			
Z	8		8			
Mu (mm-1)	0.092		0.092			
F000	1376.0		1376.0			
F000'	1376.66					
h,k,lmax	17,9,42		17,9,42			
Nref	3693		3673			
Tmin, Tmax	0.982,0.986		0.654,0.74	6		
Tmin'	0.982					
Correction method= # Reported T Limits: Tmin=0.654 Tmax=0.746						
AbsCorr = MULTI	-SCAN					
Data completeness= 0.995 Theta(max)= 27.500)		
R(reflections) = 0.0451(2507) wR2(reflections) = 0.1173(3673)						
S = 1.065	Npa	r = 226				